Inter-hospital heterogeneity in the authorizations of off-label cancer drugs: A project by Associazione Italiana di Oncologia Medica
Tumori Journal · 2025
DOI: 10.1177/03008916251386285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tumori Journal, 2025. Verfasst von Anna Amela Valsecchi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University of Turin, A.O.U. Città della Salute e della Scienza di Torino, Ospedale Molinette, Turin, Italy. Hauptthemen laut MEDLINE: Off-Label Use, Antineoplastic Agents, Neoplasms. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
Purpose
This project aimed to describe variability of local evaluations of off-label cancer drug requests by submitting a list of identical requests to different Italian centers.
Methods
In October 2024, oncology unit directors listed in the AIOM Libro Bianco were invited to participate, evaluating 11 clinical cases with solid tumors through their internal approval process. Supporting evidence was retrospective in two cases, based on phase II trials in seven, and phase III trials in two. Inter-rater agreement was measured using Fleiss’ kappa.
Results
Seven centers completed evaluations. Two cases were approved by all centers, both with a rare cancer with scant alternatives. The mean number of centers approving the individual requests was 5.36/7 (76.6%) with a poor inter-rater agreement (kappa 0.009, 95% CI -0.120 to 0.138). Single centers approved a mean of 8.4 requests (76.6%). The mean number of centers that approved requests was 5.5 for requests based on retrospective studies, 5.3 for those based on phase II trials, and 5.5 for those based on phase III trials. There was no correlation between estimated cost and chance of approval.
Conclusions
There is a significant inter-hospital variability in off-label oncology drug evaluations, leading to potential disparities in patient’s access to care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, University of Turin, A.O.U. Città della Salute e della Scienza di Torino, Ospedale Molinette, Turin, Italy.
- SC Farmacia Ospedaliera, AOU Città della Salute e della Scienza di Torino, Turin, Italy.
- UOC Oncologia Medica, Azienda Ospedaliero-Universitaria di Parma; Dipartimento di Medicina e Chirurgia, Università di Parma, Parma, Italy.
- SC Oncologia AO S. Croce e Carle, Cuneo, Italy.
- UOC Oncologia Medica, Presidio Ospedaliero di Pescara, Pescara, Italy.
- SC Oncologia, Polo Oncologico P.O. Manerbio, ASST del Garda, Manerbio, Italy.
ORCID-Profile: Anna Amela Valsecchi, Matilde Scaldaferri, Gianmauro Numico, Nicola Personeni, Massimo Di Maio
Zitieren
APA
Valsecchi, A. A., Scaldaferri, M., Tiseo, M., Numico, G., Russo, G., Personeni, N., Blasi, L., Pisterna, A., Zanardi, A., Fruttero, C., Beretta, G. D., Dusi, G., Campione, M., Gennari, A., Chiappetta, M. R., Perrone, F., & Di Maio, M. (2025). Inter-hospital heterogeneity in the authorizations of off-label cancer drugs: A project by Associazione Italiana di Oncologia Medica. Tumori Journal. https://doi.org/10.1177/03008916251386285
Vancouver
Valsecchi AA, Scaldaferri M, Tiseo M, Numico G, Russo G, Personeni N, et al. Inter-hospital heterogeneity in the authorizations of off-label cancer drugs: A project by Associazione Italiana di Oncologia Medica. Tumori Journal. 2025. doi:10.1177/03008916251386285
BibTeX
@article{Valsecchi2025,
author = {Valsecchi, Anna Amela and Scaldaferri, Matilde and Tiseo, Marcello and Numico, Gianmauro and Russo, Gianluca and Personeni, Nicola and Blasi, Livio and Pisterna, Alessia and Zanardi, Alessandra and Fruttero, Claudia and Beretta, Giordano Domenico and Dusi, Giulia and Campione, Marina and Gennari, Alessandra and Chiappetta, Maria Rachele and Perrone, Francesco and Di Maio, Massimo},
title = {Inter-hospital heterogeneity in the authorizations of off-label cancer drugs: A project by Associazione Italiana di Oncologia Medica},
journal = {Tumori Journal},
year = {2025},
doi = {10.1177/03008916251386285}
}
EUVIMED